Asset Details
Do you wish to reserve the book?
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Do you wish to request the book?
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
2006
Overview
Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) show promise in colorectal cancer prevention, but there have been concerns about potential toxicity. Pharmacogenetic studies to establish an individual's risk– benefit ratio might allow tailoring of chemoprevention.
Key Points
Non-steroidal anti-inflammatory drugs (NSAIDs) are effective chemopreventive agents against colorectal neoplasia.
NSAID use is associated with a reduced risk of several other types of malignancies, but randomized controlled trials for primary or secondary prevention are still needed.
A key mechanism for NSAID efficacy is cyclooxygenase (COX) inhibition and reduced production of prostaglandins.
COX2-specific inhibitors (COXibs) might be less toxic to the gastrointestinal tract than NSAIDs that target both COX1 and COX2. However, cardiovascular toxicity associated with COXibs raises concerns.
Inherited genetic factors can explain some inter-individual differences in NSAID metabolism and prostaglandin synthesis.
Initial epidemiological studies indicate that only in a genetically defined subset of the population will NSAIDs prevent colorectal neoplasia, which suggests pharmacogenetic effects.
Pharmacogenetic investigations are expected to help establish the individual risk–benefit ratio for NSAID use and therefore allow tailoring of chemoprevention.
In general, a multi-agent, multi-targeted approach to chemoprevention is to be recommended. However, NSAIDs are effective as single agents because they work early in carcinogenesis across multiple pathways.
Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) show indisputable promise as chemopreventive agents. Possible targets include cancers of the colon, stomach, breast and lung. However, recent studies raise concern about potential cardiovascular toxicity associated with the use of NSAIDs that specifically target the enzyme cyclooxygenase 2. These findings, and others that show that inherited genetic characteristics might determine preventive success, argue for new strategies that are tailored to individual medical history and genetic make-up.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
/ Anti-Inflammatory Agents, Non-Steroidal - pharmacology
/ Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
/ Biomedical and Life Sciences
/ Cancer
/ Cyclooxygenase 2 Inhibitors - adverse effects
/ Cyclooxygenase 2 Inhibitors - pharmacology
/ Cyclooxygenase 2 Inhibitors - therapeutic use
/ Humans
/ Neoplasms - prevention & control
